Risk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease—Do We Already Know Everything?
Abstract
:1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
3.1. Characteristics of the Groups
3.2. Risk Factors for Osteoporosis in Patients with IBD
3.3. Logistic Regression Model for Osteoporosis in Patients with IBD
3.4. Comparison between Patients with IBD and Patients from the General Population
4. Discussion
Strengths and Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Łodyga, M.; Eder, P.; Gawron-Kiszka, M.; Dobrowolska, A.; Gonciarz, M.; Hartleb, M.; Kłopocka, M.; Małecka-Wojciesko, E.; Radwan, P.; Reguła, J.; et al. Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Gastroenterol. Rev./Przegląd Gastroenterol. 2021, 16, 257–296. [Google Scholar] [CrossRef] [PubMed]
- Eder, P.; Łodyga, M.; Łykowska-Szuber, L.; Bartnik, W.; Durlik, M.; Gonciarz, M.; Kłopocka, M.; Linke, K.; Małecka-Panas, E.; Radwan, P.; et al. Guidelines for the management of ulcerative colitis. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology. Gastroenterol. Rev./Przegląd Gastroenterol. 2013, 8, 1–20. [Google Scholar] [CrossRef]
- Lima, C.; Lyra, A.; Rocha, R.; Santana, G. Risk factors for osteoporosis in inflammatory bowel disease patients. World J. Gastrointest. Pathophysiol. 2015, 6, 210–218. [Google Scholar] [CrossRef] [PubMed]
- Camacho, P.; Petak, S.; Binkley, N.; Diab, D.L.; Eldeiry, L.S.; Farooki, A.; Harris, S.T.; Hurley, D.L.; Kelly, J.; Lewiecki, E.M.; et al. American association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr. Pract. 2020, 26, 1–46. [Google Scholar] [CrossRef]
- Kärnsund, S.; Lo, B.; Bendtsen, F.; Holm, J.; Burisch, J. Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. World J. Gastroenterol. 2020, 26, 5362–5374. [Google Scholar] [CrossRef]
- Reffitt, D.M.; Meenan, J.; Sanderson, J.D.; Jugdaohsingh, R.; Powell, J.J.; Thompson, R.P. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2003, 15, 1267–1273. [Google Scholar] [CrossRef]
- Kanis, J.; Cooper, C.; Rizzoli, R.; Reginster, J.Y. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif. Tissue Int. 2019, 104, 235–238. [Google Scholar] [CrossRef]
- Parthan, A.; Kruse, M.; Yurgin, N.; Huang, J.; Viswanathan, H.N.; Taylor, D. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl. Health Econ. Health Policy 2013, 11, 485–497. [Google Scholar] [CrossRef]
- Zagórowicz, E.; Walkiewicz, D.; Kucha, P.; Perwieniec, J.; Maluchnik, M.; Wieszczy, P.; Reguła, J. Nationwide data on epidemiology of inflammatory bowel disease in Poland between 2009 and 2020. Pol. Arch. Intern. Med. 2022, 132, 16194. [Google Scholar]
- Schüle, S.; Rossel, J.; Frey, D.; Biedermann, L.; Scharl, M.; Zeitz, J.; Freitas-Queiroz, N.; Kuntzen, T.; Greuter, T.; Vavricka, S.R.; et al. Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. Medicine 2017, 96, e6788. [Google Scholar] [CrossRef] [Green Version]
- Ratajczak, A.; Szymczak-Tomczak, A.; Michalak, M.; Rychter, A.M.; Zawada, A.; Dobrowolska, A.; Krela-Kaźmierczak, I. The associations between vitamin D, bone mineral density and the course of inflammatory bowel disease in Polish patients. Pol. Arch. Intern. Med. 2022, 26, 16329. [Google Scholar] [CrossRef] [PubMed]
- Leslie, W.; Miller, N.; Rogala, L.; Bernstein, C.N. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: The Manitoba IBD Cohort Study. Am. J. Gastroenterol. 2008, 103, 1451–1459. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haugeberg, G.; Vetvik, K.; Stallemo, A.; Bitter, H.; Mikkelsen, B.; Stokkeland, M. Bone density reduction in patients with Crohn disease and associations with demographic and disease variables: Cross-sectional data from a population-based study. Scand. J. Gastroenterol. 2001, 36, 759–765. [Google Scholar] [CrossRef] [PubMed]
- Jahnsen, J.; Falch, J.A.; Aadland, E.; Mowinckel, P. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: A population based study. Gut 1997, 40, 313–319. [Google Scholar] [CrossRef]
- Turk, N.; Cukovic-Cavka, S.; Korsic, M.; Turk, Z.; Vucelic, B. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn’s disease. Eur. J. Gastroenterol. Hepatol. 2009, 21, 159–166. [Google Scholar] [CrossRef] [Green Version]
- Rychter, A.; Ratajczak, A.; Szymczak-Tomczak, A.; Michalak, M.; Eder, P.; Dobrowolska, A.; Krela-Kaźmierczak, I. Associations of Lifestyle Factors with Osteopenia and Osteoporosis in Polish Patients with Inflammatory Bowel Disease. Nutrients 2021, 13, 1863. [Google Scholar] [CrossRef]
- Mauro, M.; Armstrong, D. Evaluation of densitometric bone-muscle relationships in Crohn’s disease. Bone 2007, 40, 1610–1614. [Google Scholar] [CrossRef]
- Lee, N.; Radford-Smith, G.L.; Forwood, M.; Wong, J.; Taaffe, D.R. Body composition and muscle strength as predictors of bone mineral density in Crohn’s disease. J. Bone Miner. Metab. 2009, 27, 456–463. [Google Scholar] [CrossRef]
- Vestergaard, P.; Krogh, K.; Rejnmark, L.; Laurberg, S.; Mosekilde, L. Fracture risk is increased in Crohn’s disease, but not in ulcerative colitis. Gut 2000, 46, 176–181. [Google Scholar] [CrossRef]
- Vestergaard, P.; Mosekilde, L. Fracture risk in patients with celiac Disease, Crohn’s disease, and ulcerative colitis: A nationwide follow-up study of 16,416 patients in Denmark. Am. J. Epidemiol. 2002, 156, 1–10. [Google Scholar] [CrossRef] [Green Version]
- Capozzi, A.; Scambia, G.; Migliaccio, S.; Lello, S. Role of vitamin K2 in bone metabolism: A point of view and a short reappraisal of the literature. Gynecol. Endocrinol. 2020, 36, 285–288. [Google Scholar] [CrossRef] [PubMed]
- Sánchez-Cano, D.; Ruiz-Villaverde, R.; Callejas-Rubio, J.L.; Pérez, C.C.; García, M.G. Vitamin D deficiency and bone mineral density in Crohn’s disease. Med. Clin. 2011, 137, 62–65. [Google Scholar]
- Compston, J.E.; Creamer, B. Plasma levels and intestinal absorption of 25-hydroxyvitamin D in patients with small bowel resection. Gut 1977, 18, 171–175. [Google Scholar] [CrossRef] [Green Version]
- Gubatan, J.; Moss, A.C. Vitamin D in inflammatory bowel disease: More than just a supplement. Curr. Opin. Gastroenterol. 2018, 34, 217–225. [Google Scholar] [CrossRef] [PubMed]
- Ardizzone, S.; Bollani, S.; Bettica, P.; Bevilacqua, M.; Molteni, P.; Porro, G.B. Altered bone metabolism in inflammatory bowel disease: There is a difference between Crohn’s disease and ulcerative colitis. J. Intern. Med. 2000, 247, 63–70. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schoon, E.J.; Geerling, B.G.; Van Dooren, I.M.A.; Schurgers, L.J.; Vermeer, C.; Brummer, R.J.; Stockbrügger, R.W. Abnormal bone turnover in long-standing Crohn’s disease in remission. Aliment Pharmacol. Ther. 2001, 15, 783–792. [Google Scholar] [CrossRef]
- Abreu, M.T.; Kantorovich, V.; Vasiliauskas, E.A.; Schurgers, L.; Vermeer, C.; Brummer, R.-J.M.; Stockbrügger, R.W. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn’s disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut. 2004, 53, 1129–1136. [Google Scholar] [CrossRef] [Green Version]
- Szathmári, M.; Prónai, L.; Tulassay, Z. Altered bone metabolism in inflammatory bowel disease. Am. J. Gastroenterol. 1998, 93, 848–849. [Google Scholar] [CrossRef]
- Tulewicz-Marti, E.M.; Lewandowski, K.; Rydzewska, G. Bone Metabolism Alteration in Patients with Inflammatory Bowel Disease. J. Clin. Med. 2022, 11, 4138. [Google Scholar] [CrossRef]
- WHO Scientific Group on the Prevention and Management of Osteoporosis. Prevention and Management of Osteoporosis: Report of a WHO Scientific Group; World Health Organization: Geneva, Switzerland, 2003; Volume 921, pp. 1–164.
- Sigurdsson, G.V.; Schmidt, S.; Mellström, D.; Ohlsson, C.; Karlsson, M.; Lorentzon, M.; Saalman, R. Physical exercise is associated with beneficial bone mineral density and body composition in young adults with childhood-onset inflammatory bowel disease. Scand. J. Gastroenterol. 2021, 56, 699–707. [Google Scholar] [CrossRef]
Variable | Patients with IBD | Control Group | MD/Cramer V (95% CI) | p |
---|---|---|---|---|
N | 232 (100.0) | 199 (100.0) | - | - |
Age, years | 42.09 ± 14.38 | 54.00 ± 12.57 | −11.91 (−14.49;−9.33) | <0.001 |
Gender | ||||
Female | 121 (52.2) | 140 (70.4) | 0.19 (0.09;0.27) | <0.001 |
Male | 111 (47.8) | 59 (29.6) | ||
BMI | 23.21 (20.06;25.80) | 23.24 (19.88;26.37) | −0.03 (−0.78;0.76) | 0.997 |
IBD | ||||
Ulcerative colitis | 79 (34.1) | - | - | - |
Crohn’s disease | 153 (65.9) | - | - | - |
Crohn’s disease - location | ||||
Small intestine | 69 (29.7) | - | - | - |
Large intestine | 59 (25.4) | - | - | - |
Ileocecal | 73 (31.5) | - | - | - |
Ulcerative colitis - location | ||||
Pancolitis | 54 (23.3) | - | - | - |
Left-sided | 5 (2.2) | - | - | - |
Proctitis | 20 (8.6) | - | - | - |
Remission | 87 (37.5) | - | - | - |
Exacerbation | 145 (62.5) | - | - | - |
Smoking | 27 (11.6) | 42 (21.1) | 0.13 (0.04;0.22) | 0.011 |
Physical activity | ||||
Everyday | 65 (28.0) | 7 (3.5) | 0.39 (0.32;0.46) | <0.001 |
Once a week | 76 (32.8) | 47 (23.6) | ||
Rarely | 57 (24.6) | 95 (47.7) | ||
Not physically active | 34 (14.7) | 50 (25.1) | ||
Physical activity form | ||||
Jogging | 34 (14.7) | - | - | - |
Cycling | 51 (22.0) | - | - | - |
Gymnastics | 46 (19.8) | - | - | - |
Swimming | 38 (16.4) | - | - | - |
Other | 78 (33.6) | - | - | - |
No information | 33 (14.2) | - | - | - |
Calcium in diet | 49 (21.1) | 30 (15.1) | 0.08 (0.01;0.17) | 0.136 |
Supplementation of vit. D and Ca | 72 (31.0) | 35 (17.6) | 0.16 (0.06;0.24) | 0.002 |
Glucocorticosteroids (latest 12 months) | 90 (38.8) | - | - | - |
Anti-TNF (latest 12 months) | 36 (15.5) | - | - | - |
Operation (latest 12 months) | 20 (8.6) | - | - | - |
Fracture | 18 (7.8) | 39 (19.6) | 0.17 (0.09;0.26) | 0.001 |
Arthralgia | 118 (50.9) | 76 (38.2) | 0.13 (0.03;0.22) | 0.011 |
Metabolic bone disease | ||||
None | 137 (59.1) | 115 (57.8) | 0.01 (0.01;0.14) | 0.956 |
Osteopenia | 78 (33.6) | 69 (34.7) | ||
Osteoporosis | 17 (7.3) | 15 (7.5) | ||
CTX, ng/mL | 0.52 ± 0.30 | 0.53 ± 0.30 | −0.01 (−0.06;0.05) | 0.780 |
Osteocalcin, ng/mL | 20.40 (13.28;30.65) | 20.40 (13.40;30.80) | 0.00 (−2.30;1.90) | 0.875 |
PTH, pg/mL | 36.20 (26.75;47.60) | 36.20 (26.00;47.60) | 0.00 (−2.60;2.90) | 0.969 |
Vit. D, ng/mL | 16.20 (8.90;20.70) | 16.20 (8.90;20.70) | 0.00 (−1.50;1.40) | 0.919 |
Variable | Risk Factors for Osteoporosis | |||
---|---|---|---|---|
Osteoporosis | No Osteoporosis | MD/Cramer V (95% CI) | p | |
N | 17 (100.0) | 215 (100.0) | - | - |
Age, years | 39.29 ± 5.03 | 42.31 ± 14.85 | −3.02 (−6.21;0.18) | 0.064 |
Gender | ||||
Female | 3 (17.6) | 118 (54.9) | 0.19 (0.08;0.30) | 0.007 |
Male | 14 (82.4) | 97 (45.1) | ||
BMI | 23.60 (15.51;23.60) | 23.18 (20.06;25.80) | 0.42 (−4.03;1.85) | 0.462 |
IBD | ||||
Ulcerative colitis | 12 (70.6) | 67 (31.2) | 0.22 (0.08;0.34) | 0.002 |
Crohn’s disease | 5 (29.4) | 148 (68.8) | ||
Crohn’s disease-location | ||||
Small intestine | 5 (29.4) | 64 (29.8) | 0.00 (0.00;0.14) | >0.999 |
Large intestine | 5 (29.4) | 54 (25.1) | 0.03 (0.00;0.16) | 0.773 |
Ileocecal | 0 (0.0) | 73 (34.0) | 0.19 (0.14;0.24) | 0.009 |
Ulcerative colitis-location | ||||
Pancolitis | 12 (70.6) | 42 (19.5) | 0.31 (0.16;0.46) | <0.001 |
Left-sided | 0 (0.0) | 5 (2.3) | 0.04 | >0.999 |
Proctitis | 0 (0.0) | 20 (9.3) | 0.09 (0.06;0.11) | 0.374 |
Remission | 0 (0.0) | 87 (40.5) | 0.22 (0.16;0.28) | 0.002 |
Exacerbation | 17 (100.0) | 128 (59.5) | 0.22 (0.16;0.27) | 0.002 |
Smoking | 0 (0.0) | 27 (12.6) | 0.10 (0.07;0.13) | 0.232 |
Physical activity | ||||
Everyday | 5 (29.4) | 60 (27.9) | 0.33 (0.22;0.45) | <0.001 |
Once a week | 0 (0.0) | 76 (35.3) | ||
Rarely | 12 (70.6) | 45 (20.9) | ||
Not physically active | 0 (0.0) | 34 (15.8) | ||
Physical activity form | ||||
Jogging | 0 (0.0) | 34 (15.8) | 0.12 (0.08;0.15) | 0.144 |
Cycling | 0 (0.0) | 51 (23.7) | 0.15 (0.11;0.19) | 0.028 |
Gymnastics | 5 (29.4) | 41 (19.1) | 0.07 (0.00;0.22) | 0.342 |
Swimming | 0 (0.0) | 38 (17.7) | 0.12 (0.09;0.16) | 0.083 |
Other | 12 (70.6) | 66 (30.7) | 0.22 (0.07;0.34) | 0.002 |
No information | 0 (0.0) | 33 (15.3) | 0.11 (0.08;0.15) | 0.141 |
Calcium in diet | 5 (29.4) | 44 (20.5) | 0.06 (0.00;0.19) | 0.366 |
Supplementation of vit. D and Ca | 5 (29.4) | 67 (31.2) | 0.01 (0.00;0.14) | >0.999 |
Glucocorticosteroids (latest 12 months) | 9 (52.9) | 81 (37.7) | 0.08 (0.01;0.22) | 0.325 |
Anti-TNF (latest 12 months) | 0 (0.0) | 36 (16.7) | 0.12 (0.09;0.16) | 0.082 |
Operation (latest 12 months) | 0 (0.0) | 20 (9.3) | 0.09 (0.06;0.12) | 0.374 |
Fracture | 8 (47.1) | 10 (4.7) | 0.41 (0.18;0.64) | <0.001 |
Arthralgia | 9 (52.9) | 109 (50.7) | 0.01 (0.00;0.15) | >0.999 |
Bone disease | ||||
None | 0 (0.0) | 137 (63.7) | - | <0.001 |
Osteopenia | 0 (0.0) | 78 (36.3) | ||
Osteoporosis | 17 (100.0) | 0 (0.0) | ||
CTX, mg/mL | 0.49 (0.49;0.57) | 0.43 (0.28;0.70) | 0.06 (0.01;0.22) | 0.045 |
Osteocalcin, ng/mL | 12.70 (10.90;19.20) | 22.00 (13.50;31.10) | −9.30 (−12.10;−1.20) | 0.007 |
PTH, pg/mL | 45.70 (28.90;65.30) | 36.20 (26.00;47.60) | 9.50 (−0.90;16.40) | 0.115 |
Vit. D, ng/mL | 14.60 (8.80;15.70) | 16.30 (9.10;21.20) | −1.70 (−5.80;1.30) | 0.199 |
Variable | Patients with IBD|Univariate Model | Patients with IBD|Multivariate Model | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Coeff | SE | OR | 95% CI | p | Coeff | SE | OR | 95% CI | p | |
Age, years | −0.02 | 0.02 | 0.98 | 0.94–1.02 | 0.406 | −0.28 | 0.12 | 0.76 | 0.56–0.92 | 0.021 |
Gender, male (vs female) | 1.74 | 0.65 | 5.68 | 1.79–25.14 | 0.008 | 8.69 | 3.94 | 5937.15 | 19.70–4.40 × 108 | 0.028 |
BMI | −0.02 | 0.05 | 0.98 | 0.88–1.08 | 0.768 | - | - | - | - | - |
Crohn’s disease (vs ulcerative colitis) | −1.67 | 0.55 | 0.19 | 0.06–0.53 | 0.003 | −7.35 | 2.73 | 0.00 | 0.00–0.05 | 0.007 |
Localization CD, small intestine | −0.02 | 0.55 | 0.98 | 0.30–2.77 | 0.975 | - | - | - | - | - |
Localization CD, large intestine | 0.22 | 0.56 | 1.24 | 0.38–3.52 | 0.696 | - | - | - | - | - |
Localization UC, pancolitis | 2.29 | 0.56 | 9.89 | 3.47–32.50 | <0.001 | - | - | - | - | - |
Smoking | - | - | - | - | - | 11.17 | 6842.21 | 71,174.32 | 0.00–1.41 × 10105 | 0.999 |
Rarely (vs every day) | 1.16 | 0.57 | 3.2 | 1.10–10.66 | 0.040 | 5.93 | 2.62 | 374.85 | 7.74–339,510.40 | 0.023 |
Gymnastics | 0.57 | 0.56 | 1.77 | 0.54–5.06 | 0.309 | - | - | - | - | - |
Other physical activity type | 1.69 | 0.55 | 5.42 | 1.93–17.60 | 0.002 | 4.93 | 2.32 | 138.50 | 3.03–34,011.20 | 0.033 |
Calcium in diet | 0.48 | 0.56 | 1.62 | 0.49–4.62 | 0.388 | - | - | - | - | - |
Supplementation of vit. D and Ca | −0.08 | 0.55 | 0.92 | 0.28–2.59 | 0.881 | - | - | - | - | - |
Glucocorticosteroids (last 12 months) | 0.62 | 0.51 | 1.86 | 0.69–5.14 | 0.219 | - | - | - | - | - |
Fracture | 2.90 | 0.58 | 18.22 | 5.79–58.70 | <0.001 | 0.86 | 1.27 | 2.37 | 0.14–35.68 | 0.496 |
Arthralgia | 0.09 | 0.50 | 1.09 | 0.40–3.02 | 0.859 | - | - | - | - | - |
CTX, ng/mL | 0.76 | 0.78 | 2.14 | 0.42–9.40 | 0.331 | - | - | - | - | - |
Osteocalcin, ng/mL | −0.07 | 0.03 | 0.94 | 0.88–0.98 | 0.018 | - | - | - | - | - |
PTH, pg/mL | 0.02 | 0.01 | 1.02 | 0.99–1.04 | 0.211 | - | - | - | - | - |
Vit. D, ng/mL | −0.06 | 0.04 | 0.94 | 0.87–1.00 | 0.100 | - | - | - | - | - |
Variable | With IBD | Control Group | MD/Cramer V (95% CI) | p |
---|---|---|---|---|
N | 17 (100.0) | 15 (100.0) | - | - |
Age, years | 39.29 ± 5.03 | 46.87 ± 12.96 | −7.57 (−14.51;−0.64) | 0.033 |
Gender | ||||
Female | 3 (17.6) | 10 (66.7) | 0.50 (0.14;0.81) | 0.014 |
Male | 14 (82.4) | 5 (33.3) | ||
BMI | 23.60 (15.51;23.60) | 23.60 (18.00;29.00) | 0.00 (−5.49;5.49) | 0.801 |
Smoking | 0 (0.0) | 2 (13.3) | 0.27 | 0.212 |
Physical activity | ||||
Every day | 5 (29.4) | 0 (0.0) | 0.53 | 0.015 |
Once a week | 0 (0.0) | 3 (20.0) | ||
Rarely | 12 (70.6) | 11 (73.3) | ||
Not physically active | 0 (0.0) | 1 (6.7) | ||
Calcium in diet | 5 (29.4) | 4 (26.7) | 0.03 (0.00;0.38) | >0.999 |
Supplementation of vit. D and Ca | 5 (29.4) | 2 (13.3) | 0.19 (0.01;0.49) | 0.402 |
Fracture | 8 (47.1) | 8 (53.3) | 0.06 (0.00;0.44) | >0.999 |
Arthralgia | 9 (52.9) | 2 (13.3) | 0.42 (0.11;0.70) | 0.048 |
T-score femoral neck | −1.31 ± 1.74 | −2.30 (−2.60;−1.20) | 0.00 (−0.40;0.40) | 0.922 |
Z-score femoral neck | −2.10 (−2.30;−1.00) | −2.10 (−-2.20;−1.00) | 0.00 (−0.20;0.20) | 0.953 |
T-score lumbar spine | −2.90 (−4.90;−1.50) | −2.50 (−3.90;−2.00) | −0.40 (−1.00;1.00) | 0.907 |
Z-score lumbar spine | −3.90 (−4.90;−1.10) | −2.40 (−4.40;−1.60) | −1.50 (−1.30;1.00) | 0.861 |
CTX, mg/mL | 0.49 (0.49;0.57) | 0.49 (0.49;0.57) | 0.00 (0.00;0.09) | 0.742 |
Osteocalcin, ng/mL | 12.70 (10.90;19.20) | 12.70 (10.90;19.55) | 0.00 (−4.50;4.50) | 0.954 |
PTH, pg/mL | 45.70 (28.90;65.30) | 45.70 (27.95;55.50) | 0.00 (−11.90;16.80) | 0.684 |
Vit. D, ng/mL | 14.60 (8.80;15.70) | 14.60 (8.80;15.70) | 0.00 (−5.60;1.70) | 0.848 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lewandowski, K.; Kaniewska, M.; Więcek, M.; Szwarc, P.; Panufnik, P.; Tulewicz-Marti, E.; Walicka, M.; Franek, E.; Rydzewska, G. Risk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease—Do We Already Know Everything? Nutrients 2023, 15, 1151. https://doi.org/10.3390/nu15051151
Lewandowski K, Kaniewska M, Więcek M, Szwarc P, Panufnik P, Tulewicz-Marti E, Walicka M, Franek E, Rydzewska G. Risk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease—Do We Already Know Everything? Nutrients. 2023; 15(5):1151. https://doi.org/10.3390/nu15051151
Chicago/Turabian StyleLewandowski, Konrad, Magdalena Kaniewska, Martyna Więcek, Paulina Szwarc, Paulina Panufnik, Edyta Tulewicz-Marti, Magdalena Walicka, Edward Franek, and Grażyna Rydzewska. 2023. "Risk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease—Do We Already Know Everything?" Nutrients 15, no. 5: 1151. https://doi.org/10.3390/nu15051151
APA StyleLewandowski, K., Kaniewska, M., Więcek, M., Szwarc, P., Panufnik, P., Tulewicz-Marti, E., Walicka, M., Franek, E., & Rydzewska, G. (2023). Risk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease—Do We Already Know Everything? Nutrients, 15(5), 1151. https://doi.org/10.3390/nu15051151